Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quentin M Anstee

Showing results (171-180 of 261) with videos related to

Pageof 27
Sort By:
Contemporary Clinical Trials|November 9, 2018
European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationaleJake P Mann, Anita Vreugdenhil, Piotr Socha, et al.
Journal of Hepatology|February 16, 2019
The degree of hepatic steatosis associates with impaired cardiac and autonomic functionDavid Houghton, Paweł Zalewski, Kate Hallsworth, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2022
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' replyDanielle Brandman, Marie Boyle, Stuart McPherson, et al.
Gastroenterology|February 7, 2020
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisRod S Taylor, Rebecca J Taylor, Sue Bayliss, et al.
Journal of Hepatology|April 30, 2023
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastographyJia-Xu Liang, Javier Ampuero, Hao Niu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 16, 2025
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related MortalityCarolin V Schneider, Stefan Gross, Sriram Balasubramani, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
Journal of Hepatology|February 26, 2017
Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLDPanu K Luukkonen, You Zhou, P A Nidhina Haridas, et al.
Pageof 27

Showing results (171-180 of 261) with videos related to

Sort By:
Pageof 27
Contemporary Clinical Trials|November 9, 2018
European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationaleJake P Mann, Anita Vreugdenhil, Piotr Socha, et al.
Journal of Hepatology|February 16, 2019
The degree of hepatic steatosis associates with impaired cardiac and autonomic functionDavid Houghton, Paweł Zalewski, Kate Hallsworth, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2022
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' replyDanielle Brandman, Marie Boyle, Stuart McPherson, et al.
Gastroenterology|February 7, 2020
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisRod S Taylor, Rebecca J Taylor, Sue Bayliss, et al.
Journal of Hepatology|April 30, 2023
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastographyJia-Xu Liang, Javier Ampuero, Hao Niu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 16, 2025
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related MortalityCarolin V Schneider, Stefan Gross, Sriram Balasubramani, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
Journal of Hepatology|February 26, 2017
Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLDPanu K Luukkonen, You Zhou, P A Nidhina Haridas, et al.
Pageof 27